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We propose that such cases be designated as tissue involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma-like cells of uncertain significance. 
INTRODUCTION

DESIGN AND METHODS
Case selection and clinical review
The study was approved by the institutional review boards of the University of Pittsburgh and The signal patterns from a minimum of 200 cells were scored, and cutoffs to determine positive samples were established for each probe based on individual laboratory experience with clinical specimens.
Massachusetts General Hospital (MGH
Follow-up
Progression was defined as new or increased LAD detected on radiologic studies or physical examination after the time of diagnosis. Dates and types of treatments and clinical responses were recorded. Patients who progressed or were treated for CLL/SLL were compared to patients with at least one year of follow-up who showed no progression and were not treated. Overall and disease-specific survivals were determined for all patients.
Statistical analysis
Statistical analyses, including two-tailed t-tests, two-tailed Fisher's exact tests, Mann-Whitney test, and survival curves (log rank test) were calculated using the Prism software package, version 5 (GraphPad Software, Inc, La Jolla, CA, USA). compared with the patients in the current study), and none of these MBL patients had LAD involving more than 2 lymph node regions (p<0.0001 compared with the patients in the current study). Combining physical exam and radiologic studies, 34/36 patients (94%) had detectable LAD. Three patients had splenomegaly, while hepatomegaly was not identified in any patients.
RESULTS
Clinical features
At diagnosis, the patients had a median absolute lymphocyte count (ALC) of 2. 
Gross and microscopic features of the extramedullary tissue biopsies
The specimens included 31 excisional lymph node biopsies, 3 lymph node core biopsies, 1 nasopharyngeal tissue biopsy, and 1 breast core biopsy (Table 2) . Excisional lymph node biopsies performed in 31 patients had a median greatest dimension of 2.0 cm (range 0.9-5.2 cm).
In 4 
Follow-up
Five patients were treated for CLL/SLL. These included 2 patients treated within one month of diagnosis due to symptomatic disease (progressive myopathy attributed to CLL cell infiltration in one patient and bulky LAD in one patient) and 3 patients treated for disease progression at 5, 19, Over the follow-up period, the peripheral blood ALC remained <5.0x10 9 /L in 25/36 patients (69%), all of whom had CBC results available at the latest followup. Eight of the remaining 11
patients at least doubled their ALC at a median of 27 months after diagnosis (range 3-104 months). Although flow cytometric immunophenotypic studies were not performed to determine if the absolute MBL count qualified for a diagnosis of CLL, the ALC in these 8 patients ranged from 8.6-38.2x10 9 /L and represented 228% -1091% of the original ALC at diagnosis. These 8 patients included 2 patients who did not develop progressive LAD and 6 patients who had been treated and/or developed progressive LAD.
Correlation of pathological and clinical features
The following parameters showed no association with progression/treatment: age; gender; Rai or Binet stage; number of involved lymph node sites; palpable LAD on physical exam; splenomegaly; or IPI score. The 3 patients with spontaneously regressed LAD all had more than one site of LAD at diagnosis. There was no association between any hematologic parameters, including ALC and absolute PB MBC count at diagnosis (see Table 1 ), and progression/treatment. In 4/12 patients (33%) who progressed or required therapy, the CLL infiltrate was discovered incidentally in a biopsy performed for reasons other than LAD, and palpable LAD as reason for the biopsy was not associated with progression/treatment. There were no statistically significant differences in the size of the biopsied lymph node between patients with and without progression/treatment, nor were maximal lymph node diameters of greater than 1 cm, 1.5 cm, or 3 cm associated with progression or treatment. However, detection of any lymph node ≥ 1.5 cm in diameter on radiologic staging studies was associated with progression/treatment (p=0.02, log rank test for time to progression/treatment) and the largest lymph node size measured on CT at diagnosis was greater in patients who subsequently experienced progression or were treated (p=0.01, Mann-Whitney test) ( Figure 3B ). Of note, the largest lymph node size detected by CT on staging studies was not correlated with the diameter of the biopsied lymph node. Although the outcome of this group of patients was not specified, the authors did speculate that some of the cases could have been SLL with very low disease burden at diagnosis. (10) The disease burden in MBL is presumably reflected by the PB MBC count, which has been shown to directly correlate with progression to CLL/SLL and/or requiring therapy in multiple 18 studies. (5, (9) (10) (11) Disease burden is more difficult to assess in lymph node-based disease. In our series of patients with tissue-based disease, the ALC was not associated with progressive LAD or treatment. However, the presence of any enlarged lymph node at least 1.5 cm in diameter on CT staging at diagnosis correlated with progression/treatment. In contrast, the size of the biopsied lymph node correlated with neither progression/treatment nor the size of the largest lymph node detected on radiologic staging, suggesting that a single lymph node sampled for biopsy may not be representative of overall lymph node enlargement. There was also no correlation between palpable LAD and progression/treatment, a finding that challenges the notion that SLL should be (Table 3) . (38) A deletion 13q14.3 abnormality was more common in cases that did not progress, but this parameter did not attain statistical significance.
Achieving an appropriate definition for "involvement by CLL/SLL-like cells of uncertain significance" will require larger validation studies with longer follow-up. The results of our study suggest that cases lacking recognizable proliferation centers in patients who do not have lymphadenopathy ≥1.5 cm on CT scans are the most likely candidates for such a diagnosis.
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